RAMM Pharma

RAMM Pharma Equity Ratio

The Equity Ratio of RAMM Pharma (RAMM.CN) as of Oct 22, 2026 is 61.47 %. In the previous year, Equity Ratio was 81.41 % — a change of -24.49% (lower).

Equity Ratio

61.47 %

YoY

-24.49%

Last updated:

Equity Ratio of RAMM Pharma is 2025 61.47 % . Equity Ratio of RAMM Pharma was 2024 81.41 % . It decreases by -24.49% lower compared to the previous year.

The RAMM Pharma Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
-3.27 CAD
Jan 1, 2019
89.33 CAD
Jan 1, 2020
96.40 CAD
Jan 1, 2021
94.44 CAD
Jan 1, 2022
90.53 CAD
Jan 1, 2023
91.22 CAD
Jan 1, 2024
81.41 CAD
Jan 1, 2025
61.47 CAD
The RAMM Pharma Equity Ratio history
YEAREquity RatioYoY
61.47 %-24.49%
81.41 %-10.76%
91.22 %+0.76%
90.53 %-4.14%
94.44 %-2.03%
96.40 %+7.91%
89.33 %-2,828.08%
-3.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

Equity Ratio of RAMM Pharma is 61.47 % in 2025.

Equity Ratio of RAMM Pharma changed from 81.41 % to 61.47 %, representing a -24.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's RAMM Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RAMM Pharma

All Key Metrics — RAMM Pharma